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This study is devoted to development of the optimal conditions for synthesis and the study of some 
“structure – antioxidant activity” regularities of [(1-arylimidazole-5-yl)methylthio]alkane carboxylic ac-
ids, which structural analogues have found an application as medicinal products with a wide range of 
biological activities. The methodology of interaction between 4-cloro-5-chloromethylimidazoles with 
thioglycolic and thiopropionic acids has been used to obtain these compounds. Selection of the op-
timal reaction conditions has allowed to obtain target compounds in a dry dimethylformamide in the 
presence of potash at 50оC with yields of 75-82%. The compounds synthesized are high-melting 
crystalline substances that dissolve well in polar organic solvents and aqueous alkaline solutions. 
Their composition and structure have been confirmed by the results of elemental analysis and mea-
surement data of IR-, 1H NMR- and chromatography mass-spectra. The study of the compounds 
synthesized has been conducted in vitro on biological samples. The antioxidant activity has been 
determined by the inhibition value of the ascorbate-dependent endogenous lipid peroxidation rate in rats’ 
liver found by the concentration of one of the final products of free-radical lipid oxidation processes – 
malonaldehyde in the test sample. The results of the biological activity screening of the compounds 
synthesized show that all imidazole derivatives studied in the final concentration ranges of 10-3-10-1 M  
exhibit a high antioxidant action in the system in vitro. It has been found that the value of the antioxi-
dant activity is influenced by the nature and position of the substituent in position 1 of imidazole. In 
particular, the presence of electron-acceptor substituents in the aryl fragment decreases the molecule 
activity in comparison with electron-donor substituents, wherein increase of the methylene groups quan-
tity in the carboxyalkylthiol fragment does not significantly impact the antioxidant effect of the compounds 
synthesized.
The process of free-radical lipid oxidation (FRLO) 
plays a significant role in development of the most dis-
eases of the liver, cardiovascular, respiratory and ner-
vous systems [1, 16]. Antioxidants are widely used to 
normalize the basic organism functions as a part of com- 
plex therapy of such diseases [7]. It should be noted that 
at present there is insufficient amount of medicines with 
the antioxidant mechanism of action offered for clini-
cal use, and those that are in use have many adverse ef-
fects and high toxicity [4]. Taking this into account, the 
search of compounds that are able to inhibit the FRLO 
processes effectively is of high interest nowadays.
Design and synthesis of new compounds with anti-
oxidant properties is a subject of many studies as they 
are of high interest in prophylactics and therapy of many 
diseases that have FRLO in their pathogenesis [3, 9]. 
From this aspect the derivatives of imidazole are not 
left aside too; according to the literature data they are 
characterized by a wide spectrum of pharmacological 
properties, among which the antioxidant effect is par-
ticularly noteworthy [10, 11, 15].
Earlier we found the antioxidant activity in the se- 
ries of [(1-phenyl-5-formyl-1H-imidazole-4-yl)thio]ace- 
tic acids and their derivatives [5, 6, 8, 13]. It was to 
be expected that the change in the position of the thio-
alkanecarboxylic acid fragment in the structure of the 
imidazole cycle would allow a much bigger quantity 
of potentially active compounds with the antioxidant 
action, and also give an opportunity to approach to the 
solution of the topical problem of pharmaceutical che- 
mistry – establishing of the structure – activity relation-
ship. With this purpose we have synthesized [(1-aryl- 
imidazole-5-yl)methylthio]alkanecarboxylic acids (2а-g) 
and carried out the screening of their antioxidant pro- 
perties.
The reaction of easily available 4-chloro-5-chloro- 
metylimidazoles (1а-d) [12] with thioglycolic and thio-
propionic acids, which occurs selectively at 50оС in a 
dry DMFA in the presence of potash, has been used to 
obtain compounds of such kind. The reaction gives the 
target compounds (2а-g) with yields of 75-82%.
The compounds (2а-g) synthesized (Tab. 1, 2) are 
light-yellow, high-melting crystalline compounds, readi- 
ly soluble in polar organic solvents and aqueous alka-
line solutions. Their composition and structure were 
confirmed by elemental analysis and by the results of 
IR-, 1H NMR and chromatography mass-spectra mea-
surements. IR-spectra, in particular, are characterized 
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by intensive absorption bands of carbonyl groups at 
1675-1685 cm-1 and by a wide absorption range (2430-
2850 cm-1) of carboxyl groups, and it indicates a dime- 
ric character of the acids obtained in their solid state. In 
1H NMR spectra of all compounds the most illustrative 
are H2 proton singlets of the imidazole cycle at 7.83-
7.95 ppm and the singlets of methylene groups bound 
with the imidazole cycle at 3.72-3.85 ppm. In their turn, 
the methylene protons of thioacetic acid fragments are 
visible as singlets at 3.17 ppm, and those of thiopro-
pionic acid – as triplets in the range of 2.30-2.35 and 
2.49-2.54 ppm. 
Experimental Part (Chemistry)
IR-spectra of the compounds synthesized were re-
corded on a UR-20 spectrophotometer in KBr tablets. 
1H NMR spectra were recorded on a Varian-Mercu-
I, Ar = Ph (a), 4-FC6Н4 (b), 4-ClC6Н4 (c), 4-MeC6Н4 (d); II, n=1, Ar = 4-FC6Н4 (a),  
4-ClC6Н4 (b), 4-MeC6Н4 (c); n=2, Ar = Ph (d), 4-FC6Н4 (е), 4-ClC6Н4 (f), 4-MeC6Н4 (g)
Scheme
Table 1
Physical and chemical characteristics, data of the elemental analysis and chromatography mass spectra  










 % T melt., 
ºC Empiric formula
Found, % Calculated, %
[M+1]+ M
С Н N С Н N
2a 4-FС6Н4 75 139-140 С12H10ClFN2O2S 47.82 3.28 9.14 47.93 3.35 9.31 301 300.74
2b 4-ClС6Н4 81 86-87 С12H10Cl2N2O2S 45.64 3.28 9.01 45.44 3.18 8.83 318 317.20
2c 4-МеС6Н4 76 111-113 С13H13ClN2O2S 52.42 4.33 9.30 52.61 4.42 9.44 297 296.78
2d Рh 82 105-107 С13H13ClN2O2S 52.34 4.33 9.42 52.61 4.42 9.44 297 296.78
2e 4-FС6Н4 75 132-134 С13H12ClFN2O2S 49.34 3.79 8.77 49.61 3.84 8.90 315 314.77
2f 4-ClС6Н4 79 100-102 С13H12Cl2N2O2S 47.07 3.62 8.33 47.14 3.65 8.46 332 331.22
2g 4-МеС6Н4 75 142-144 С14H15ClN2O2S 53.88 4.75 8.87 54.10 4.86 9.01 311 310.80
Table 2







1H NMR, δ, ppm
C=O COOH
2a 1685 2430-2850 3.17 s (2Н, CH2), 3.82 s (2Н, CH2), 7.36-7.43 m (2Harom.), 7.60-7.65 m (2Harom.), 7.87 c (1H, H
2
imidazole), 
12.55 br.s. (1Н, СООН)
2b 1680 2450-2840 3.17 s (2Н, CH2), 3.85 s (2Н, CH2), 7.57-7.63 m (4Harom.), 7.90 s (1H, H2 imidazole), 12.60 br.s. (1Н, СООН)
2c 1680 2450-2820 2.38 s (3Н, CH3), 3.17 s (2Н, CH2), 3.82 s (2Н, CH2), 7.36 d (2Hаром., J 8.0 Hz), 7.41 d (2Harom., J 8.0 Hz), 7.83 s (1H, H2 imidazole), 12.54 br.s. (1Н, СООН)
2d 1675 2435-2830 2.34 t (2Н, CH2, J 6.8 Hz), 2.54 t (2Н, CH2, J 6.8 Hz),  3.75 s (2Н, CH2), 7.49-7.55 m (5Harom.),  7.87 s (1H, H2 imidazole), 12.24 s. (1Н, СООН)
2e 1680 2440-2835 2.32 t (2Н, CH2, J 6.8 Hz), 2.50 t (2Н, CH2, J 6.8 Hz), 3.77 s (2Н, CH2), 7.40-7.48 m (2Harom.),  7.62-7.69 m (2Harom.), 7.90 s (1H, H2 imidazole), 12.28 br.s. (1Н, СООН)
2f 1680 2435-2850 2.35 t (2Н, CH2, J 6.8 Hz), 2.49 t (2Н, CH2, J 6.8 Hz), 3.76 s (2Н, CH2), 7.56 d (2Harom., J 8.0 Hz),  7.64 d (2Harom., J 8.0 Hz), 7.94 s (1H, H2 imidazole), 12.20 br.s. (1Н, СООН)
2g 1685 2445-2840 2.30 t (2Н, CH2, J 6.8 Hz), 2.38 s (3Н, CH3), 2.53 t (2Н, CH2, J 6.8 Hz), 3.72 s (2Н, CH2),  7.36 d (2Harom., J 7.0 Hz), 7.42 d (2Harom., J 7.0 Hz), 7.95 s (1H, H2 imidazole), 12.40 br.s. (1Н, СООН)
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ry-400 spectrophotometer (400 MHz) in the solution 
of DMSO-d6, the inner standard – tetramethylsilane. 
Chromatography mass-spectra were recorded by a PE 
SCXAPI 150 ЕХ device, UV (250 nm) and ELSOJ de-
tectors.
{[(1-Aryl-4-chloro-1Н-imidazole-5-yl)methyl]
thio}acetic (propionic) acids (2 а-g). To the solution of 
2 mmoles of 5-chloromethylimidazole (1а-d) in 20 ml 
of a dry DMFA 0.55 g (4 mmoles) of potash and 0.19 g 
(2 mmoles) of thioglycolic acid (in cases of 2а-c) or 
0.21 g (2 mmoles) of thiopropionic acid (in cases of 
2d-g) were added; the mixture was stirred at 50°С for 
2 hours. After that the reaction mixture was poured into 
20 ml of water, and acidified with diluted hydrochlo-
ric acid to pH 4-5. The precipitate formed was filtered, 
washed with water, dried and crystallized from 70% 
aqueous solution of ethanol.
Experimental Part (Biology)
The research of the antioxidant activity of the com-
pounds (2а-g) synthesized was performed in vitro [14] 
and determined by the inhibition value of the ascor-
bate-dependent endogenous lipid peroxidation rate in 
rats’ liver found by the concentration of one of the fi-
nal products of free-radical lipid oxidation processes – 
malonaldehyde (MA) in the test sample. The content of 
MA was determined by the reaction with thiobarbitu-
ric acid (TBA) and was calculated in μmoles/g of the 
tissue. Statistical analysis of the results obtained was 
performed using the parametric Student’s t-test [2]. The 
value of ascorbate-induced FRLO inhibition was calcu-
lated in percents, with MA concentration in the control 
samples being equal to 100%.
The range of concentrations of the compounds syn-
thesized was chosen within the limits of concentrations 
already researched for their structural analogue, thiotri-
azoline (Т), (the manufacturer is “Arterium” corpora-
tion, Ukraine, solution for injections, 25 mg/ml), which 
has the proven antioxidant activity [7].
Results and Discussion
The results of the antioxidant activity screening of 
the compounds synthesized in vitro (Tab. 3) show that 
all compounds are able to inhibit Fe2+-ascorbate initi- 
ated FRLO in these conditions in the final concentra-
tion ranges of 10-3-10-1 M studied. Thus, the degree of 
Fe2+-ascorbate initiated FRLO inhibition in vitro of all 
original compounds synthesized was higher than the 
antioxidant activity of thiotriazoline in the same final 
concentrations. The antioxidant activity of thiotriazo- 
line in the specified range of final concentrations in 
vitro varied between 31.32% and 38.59% and was the 
highest with the final drug concentration of 10-1 M. 
With the same final concentration the highest inhibiting 
effect on the initiated FRLO was shown by compound 
2g (the degree of FRLO inhibition was 70.59%). Most 
compounds (2a, 2c, 2e, 2f) have shown the highest anti-
oxidant activity in vitro in the concentrations of 10-2 M. 
The highest antioxidant effect in vitro was recorded 
for compound 2d in the range of the final concentra-
tions of 5·10-3-10-2 M: the degree of FRLO inhibition 
was 76.47-76.25%. On average, it is 43% higher than 
the results shown by thiotriazoline in the same range of 
the final concentrations, and 37% higher than the maxi-
mum effect of thiotriazoline recorded in vitro.
Analysis of the data obtained shows that the value 
of the antioxidant activity is influenced by the nature 
and position of the substituent in position 1 of imida-
zole. In particular, the presence of electron-acceptor 
substituents in the aryl fragment decreases the molecule 
activity in comparison with electron-donor substitu-
ents, wherein increase of the methylene groups quantity 
in the carboxyalkylthiol fragment does not significantly 
impact the antioxidant effect of the compounds synthe-
sized.
CONCLUSIONS
1. By interaction of 5-chlorometylimidazoles with 
thioglycolic and thiopropionic acids new {[(1-Aryl-4-
Table 3
The antioxidant activity of {[(1-aryl-4-chloro-1Н-imidazole-5-yl)methyl]thio}alkanecarboxylic acids in vitro
Compound
Concentration, mole/l





















2a 45.68±0.19* 60.8 46.32±0.12* 60.2 44.39±0.12* 61.9 46.19±0.07* 60.3 45.16±0.12* 61.2
2b 66.26±0.25* 43.1 53.14±0.19* 54.4 44.78±0.32* 61.5 43.36±0.19* 62.8 50.31±0.31* 56.8
2c 50.44±0.19* 56.7 53.01±0.07* 54.5 44.39±0.12* 61.9 49.79±0.21* 57.2 45.42±0.19* 61.0
Control 1 100.36±0.37 – 100.36±0.37 – 100.36±0.37 – 100.36±0.37 – 100.36±0.37 –
2d 24.19±0.07* 59.0 16.73±0.07* 71.6 14.02±0.07* 76.2 13.90±0.12* 76.4 16.60±0.12* 71.9
2e 28.95±0.12* 50.9 20.07±0.12* 66.0 16.98±0.32* 71.2 29.34±0.12* 50.3 20.46±0.12* 65.3
2f 23.93±0.12* 59.4 24.58±0.19* 58.3 20.84±0.24* 64.7 35.13±0.12* 40.5 35.13±0.12* 40.5
2g 17.37±0.12* 70.5 19.56±0.07* 66.8 23.03±0.14* 61.0 26.25±0.12* 55.5 24.70±0.12* 58.1
Control 2 59.06±0.12 – 59.06±0.12 – 59.06±0.12 – 59.06±0.12 – 59.06±0.12 –
Thiotriazoline 70.64±0.56* 38.5 73.98±0.19* 35.6 77.33±0.25* 32.7 76.43±0.24* 33.5 79.13±0.12* 31.2
Control 4 115.03±0.24 – 115.03±0.24 – 115.03±0.24 – 115.03±0.24 – 115.03±0.24 –
* – valid in relation to control (р ≤ 0.05)
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chloro-1Н-imidazole-5-yl)methyl]thio}alkanecarboxylic 
acids have been synthesized.
2. All derivatives of imidazole studied in the range 
of concentrations of 10-3-10-1М show a high antioxidant 
activity in the system in vitro. The highest activity was 
recorded for compound 2d in the final concentration of 
5·10-3 M.
3. Increase of the methylene groups quantity in the 
carboxyalkylthiol fragment does not significantly affect 
the antioxidant effect of the compounds synthesized.
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СИНТЕЗ ТА ОЦІНКА АНТИОКСИДАНТНОЇ АКТИВНОСТІ {[(1-АРИЛ-4-ХЛОРО-1Н-ІМІДАЗОЛ-
5-ІЛ)МЕТИЛ]ТІО}АЛКАНКАРБОНОВИХ КИСЛОТ
А.М.Грозав, А.О.Паламар, В.О.Чорноус, І.М.Яремій, М.В.Вовк
Ключові слова: синтез; імідазол; [(1-арил-5-форміл-1H-імідазол-4-іл)тіо]оцтові кислоти; 
{[(1-арил-4-хлоро-1Н-імідазол-5-іл)метил]тіо}алканкарбонові кислоти; антиоксидантна 
активність
Дослідження присвячене розробці оптимальних умов синтезу та вивченню деяких закономір-
ностей «структура-антиоксидантна активність» [(1-арилімідазол-5-іл)метилтіо]алканкар-
бонових кислот, структурні аналоги яких знайшли застосування в ролі лікарських засобів із 
широким спектром біологічної дії. Для отримання зазначених сполук було використано мето-
дологію, що полягає у взаємодії 4-хлоро-5-хлорометилімідазолів з тіогліколевою та тіопро-
пановою кислотами. Підбір оптимальних умов перебігу реакції дозволив отримати цільові 
сполуки в сухому ДМФА в присутності поташу при 50оС з виходами 75-82%. Синтезовані спо-
луки – високоплавкі кристалічні речовини, що добре розчиняються в полярних органічних роз-
чинниках та водних розчинах лугів. Їх склад та структура підтверджені результатами еле-
ментного аналізу і даними вимірювань ІЧ-, ЯМР 1Н- та хроматомас-спектрів. Дослідження 
синтезованих сполук проводили in vitro на біологічних зразках. Антиоксидантну активність 
визначали за величиною інгібування швидкості аскорбатзалежного пероксидного окиснення 
ендогенних ліпідів у печінці щурів, яку встановлювали за концентрацією одного з кінцевих 
продуктів процесів ВРОЛ – малонового альдегіду у досліджуваному зразку. Результати скри-
нінгу біологічної активності синтезованих сполук свідчать про те, що всі досліджені похідні 
імідазолу в діапазоні кінцевих концентрацій 10-3-10-1 М проявляють високу антиоксидантну 
дію в системі in vitro. Встановлено, що на величину антиоксидантної активності впливає 
характер та положення замісника в положенні 1 імідазолу. Зокрема, присутність в арильно-
му фрагменті електроноакцепторних замісників знижує активність порівняно з електро-
нодонорними. При цьому збільшення кількості метиленових груп в карбоксіалкілтіольному 
фрагменті суттєво не впливає на антиоксидантний ефект синтезованих сполук.
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СИНТЕЗ И ОЦЕНКА АНТИОКСИДАНТНОЙ АКТИВНОСТИ {[(1-АРИЛ-4-ХЛОР-1Н-
ИМИДАЗОЛ-5-ИЛ)МЕТИЛ]ТИО}АЛКАНКАРБОНОВЫХ КИСЛОТ
А.Н.Грозав, А.А.Паламар, В.А.Чорноус, И.Н.Яремий, М.В.Вовк
Ключевые слова: синтез; имидазол; [(1-арил-5-формил-1H-имидазол-4-ил)тио]уксусные 
кислоты; {[(1-арил-4-хлоро-1Н-имидазол-5-ил)метил]тио}алканкарбоновые кислоты; 
антиоксидантная активность
Исследование посвящено разработке оптимальных условий синтеза и изучению некоторых за-
кономерностей «структура-антиоксидантная активность» [(1-арилимидазол-5-ил)метил- 
тио]алканкарбоновых кислот, структурные аналоги которых нашли применение в качестве 
лекарственных средств с широким спектром биологического действия. Для получения ука- 
занных соединений использована методология, которая заключается во взаимодействии 
4-хлор-5-хлорметилимидазолов с тиогликолевой и тиопропановой кислотами. Подбор опти- 
мальных условий протекания реакции позволил получить целевые соединения в сухом ДМФА  
в присутствии поташа при 50оС с выходами 75-82%. Синтезированные соединения – высо- 
коплавкие кристаллические вещества, хорошо растворимые в полярных органических ра-
створителях и водных растворах щелочей. Их состав и структура подтверждены резуль-
татами элементного анализа и данными измерений ИК-, ЯМР 1Н- и хроматомасс-спектров. 
Исследование синтезированных соединений проводили in vitro на биологических образцах. 
Антиоксидантную активность определяли по величине ингибирования скорости аскорбат-
зависимого перекисного окисления эндогенных липидов в печени крыс, которую устанавливали 
по концентрации одного из конечных продуктов процессов СРОЛ – малонового альдегида в 
исследуемом образце. Результаты скрининга биологической активности синтезированных 
соединений свидетельствуют о том, что все исследованные производные имидазола в ди-
апазоне конечных концентраций 10-3-10-1 М проявляют высокое антиоксидантное действие 
в системе in vitro. Установлено, что на величину антиоксидантной активности влияет ха-
рактер и положение заместителя в положении 1 имидазола. В частности, присутствие 
в арильном фрагменте электроноакцепторных заместителей снижает активность по 
сравнению с электронодонорными. При этом увеличение количества метиленовых групп в 
карбоксиалкилтиольном фрагменте существенно не влияет на антиоксидантный эффект 
синтезированных соединений.
